ProbeChem®
*Expedite Your Scientific Research*

# Data Sheet

WWW.PROBECHEM.COM

Global Supplier of Chemical Probes, Inhibitors & Agonists.

| | | |
|---|---|---|
| **Product Name** | : | Vercirnon |
| **Cat. No.** | : | PC-73249 |
| **CAS No.** | : | 698394-73-9 |
| **Molecular Formula** | : | $C_{22}H_{21}ClN_2O_4S$ |
| **Molecular Weight** | : | 444.93 |
| **Target** | : | Chemokine Receptor (CCR and CXCR) |
| **Solubility** | : | 10 mM in DMSO |




## Biological Activity

Vercirnon (GSK1605786, CCX282-B) is a potent, selective, orally bioavailable antagonist of **CCR9**, inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 of 5.4 and 3.4 nM, respectively.
Vercirnon (GSK1605786, CCX282-B) displays high selectivity for CCR9 over CCR1-12 and CX3CR1-7 (IC50>10 uM).
Vercirnon (GSK1605786, CCX282-B) is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively.
CCX282-B also inhibited mouse and rat CCR9-mediated chemotaxis.
Inhibition of CCR9 with CCX282-B results in normalization of Crohn's disease such as histopathology associated with the TNF(ΔARE) mice.

## References


Walters MJ, et al. ***J Pharmacol Exp Ther***. 2010 Oct;335(1):61-9.

Keshav S, et al. ***PLoS One***. 2013;8(3):e60094.



**Caution: Product has not been fully validated for medical applications. Lab Use Only!**



E-mail: tech@probechem.com